Welcome to our dedicated page for Bath & Body Works SEC filings (Ticker: BBWI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bath & Body Works, Inc. filings document the public-company record for a Delaware specialty retailer whose common stock trades on the New York Stock Exchange under BBWI. Recent 8-K reports furnish quarterly and full-year operating results, earnings guidance, Regulation FD disclosures, debt redemption notices and executive officer changes.
Proxy materials describe board oversight, director elections, executive compensation, shareholder voting matters and governance practices tied to the company’s Consumer First Formula, brand, product, supply chain and store assets. The filings also identify registered common stock, senior notes disclosures and capital-structure matters for a personal care and home fragrance retail business.
Bath & Body Works, Inc. identifies officer Ann Aber, its Chief Legal Officer & Corporate Secretary, as a reporting insider through a beneficial ownership statement. The data shows no reportable transactions and no securities holdings entries for her in this filing.
Bath & Body Works, Inc. plans a partial redemption of $250 million aggregate principal amount of its outstanding 7.500% Senior Notes due 2029. The company issued a notice of partial redemption on July 20, 2026.
The redemption date will be August 19, 2026. The redemption price will equal 101.250% of the principal amount of the notes being redeemed, plus accrued interest to, but excluding, the redemption date. The company states that this disclosure does not itself constitute a notice of redemption.
Voskuil Steven E reported acquisition or exercise transactions in this Form 4 filing.
Bath & Body Works director Steven E. Voskuil received an equity grant as part of his board compensation. On June 11, 2026, he was awarded 7,970 shares of Common Stock, reported at a price of $0.00 per share, reflecting a compensation-related award rather than a market purchase. Following this grant, his direct holdings increased to 41,895 shares of Bath & Body Works common stock. A footnote describes this as an annual award of restricted stock units to independent non-employee directors, indicating it is a routine element of the company’s director compensation program.
Rajlin Juan reported acquisition or exercise transactions in this Form 4 filing.
Bath & Body Works, Inc. director Juan Rajlin reported an equity compensation grant of 7,970 shares of common stock on June 11, 2026. The award is described as an annual grant of restricted stock units to independent non-employee directors and was issued at no cash cost. Following this grant, Rajlin directly owns 24,490 shares of Bath & Body Works common stock.
Bath & Body Works, Inc. reported that director James Kevin Symancyk received an annual equity grant under the company’s director compensation program. On June 11, 2026, he was awarded 7,970 shares of common stock at a stated price of $0.00 per share, classified as a grant or award acquisition. Following this transaction, Symancyk directly holds 48,349 common shares of Bath & Body Works.
Lee Danielle M. reported acquisition or exercise transactions in this Form 4 filing.
Bath & Body Works, Inc. director Danielle M. Lee reported a compensation-related equity grant. On June 11, 2026, she received 7,970 shares of common stock at $0.00 per share as an annual award of restricted stock units granted to independent non-employee directors. Following this award, her direct holdings increased to 26,181 common shares. This is not an open-market buy or sell, but part of standard director equity compensation.
STEINOUR STEPHEN D reported acquisition or exercise transactions in this Form 4 filing.
Bath & Body Works, Inc. director Stephen D. Steinour received an annual award of restricted stock units as an independent non-employee director. The award covers 7,970 shares of common stock at no cash cost, bringing his directly held shares to 56,145.
He also reports indirect ownership of common stock through two trusts, each holding 9,900 shares, and through his spouse, who holds 12,925 shares. These indirect positions reflect reported holdings rather than new market transactions.
Hondal Francis reported acquisition or exercise transactions in this Form 4 filing.
Bath & Body Works, Inc. director Francis Hondal reported an annual equity compensation grant. On June 11, 2026, Hondal received an award of 7,970 shares of common stock at $0.00 per share, described as an annual award of restricted stock units to independent non-employee directors.
After this grant, Hondal directly owned 13,611 shares of common stock. A separate entry shows indirect ownership of 15,913 shares held through The Francis A. Hondal Living Trust. No open-market purchases or sales were reported; the filing reflects routine director compensation and existing holdings.
Bath & Body Works, Inc. director Sarah E. Nash received an annual equity award in the form of restricted stock units. On June 11, 2026, she was granted 13,284 shares of common stock at no cash cost as director compensation. Following this grant, her direct holdings increased to 298,894.77 shares of common stock, which include 88.77 shares acquired through the company’s Dividend Reinvestment Plan.
Brady Lucy reported acquisition or exercise transactions in this Form 4 filing.
Bath & Body Works, Inc. director Lucy Brady reported an equity compensation award in the form of common stock. On June 11, 2026, she received a grant of 7,970 shares of common stock at no cash cost, described as an annual award of restricted stock units to independent non-employee directors. Following this grant, her direct holdings increased to 25,451.552 shares of Bath & Body Works common stock.